CREATE-X study[9] reported that after standard neoadjuvant chemotherapy with anthracycline, taxane, or both, the addition of adjuvant capecitabine is safe and effective in improving the disease-free survival and overall survival among patients with HER2- breast cancer and residual invasive disease. The gene discussed is ERBB2; the disease is breast cancer.